Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06077149 · ClinicalTrials.gov registry record · Phase 4
Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)
A Phase 4 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 4
- Development phase
- 152
- Enrollment target
NCT06077149 is a Phase 4 study that has completed, run by University of Rochester. The registered enrollment target is 152 participants.
The verdict
NCT06077149, a Phase 4 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 152 participants
- Enrollment target
Study Summary
This clinical trial is studying the newly licensed RSV vaccines in adults over age 60 years living in long-term care facilities (nursing homes) by comparing the immune response to their vaccine to adults over age 60 years living in the community.
Interventions
- BIOLOGICAL RSV vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2024-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06077149
The ClinicalTrials.gov registry entry for NCT06077149 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RSV vaccine is the first listed.
NCT06077149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06077149 about?
NCT06077149 is a clinical study titled "Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)". This clinical trial is studying the newly licensed RSV vaccines in adults over age 60 years living in long-term care facilities (nursing homes) by comparing the immune response to their vaccine to adults over age 60 years living in the community.
What is the current status of trial NCT06077149?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 152 participants. The study started on 2023-11-07. Estimated completion is 2024-11-01.
What interventions are being tested in trial NCT06077149?
The interventions under investigation include: RSV vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06077149?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.